

HPV Vaccine Session

Joseph A. Bocchini, Jr., MD
Chair, ACIP HPV Vaccine Work Group

Advisory Committee on Immunization Practices
Atlanta, GA
October 24, 2013

Review: June 2013 ACIP meeting HPV session

- ❑ Merck Vaccine in Pregnancy Registry
 - Fulfilled commitment to FDA, registry closed
- ❑ Plans for updated ACIP statement – including males/females and bivalent/quadrivalent vaccines
 - HPV infection risk for research HPV laboratory workers
 - HPV infection risk for selected health care workers
- ❑ Review of U.S. HPV vaccine program, safety data, impact monitoring data

ACIP HPV Vaccine Work Group: Conference calls

- ❑ Alternative schedules - bivalent HPV vaccine
- ❑ 9-valent HPV vaccine (cancelled)

Outline of HPV ACIP Session

- Update on HPV vaccination coverage in the US
 - Ms. Shannon Stokley, NCIRD/CDC

- 9-valent HPV vaccine development program
 - Dr. Alain Luxembourg, Merck

- Updated ACIP statement
 - Dr. Lauri Markowitz, NCHHSTP/CDC

ACIP HPV Vaccine Workgroup members

ACIP Members

Joseph Bocchini (WG chair)
Tamera Coyne-Beasley
Renee Jenkins

Ex Officio Members

Carolyn Deal (NIH)
Bruce Gellin (NVPO)
Nancy Miller (FDA)
Jeff Roberts (FDA)

CDC Lead

Lauri Markowitz

Liasion Representatives

Sandra Fryhofer (ACP)
Amy Middleman (SAM)
James Turner (ACHA)
Patricia Whitley-Williams (NMA)
Rodney Willoughby (AAP)
Jane Zucker (AIM)
Margo Savoy (AAFP)
Linda Eckert (AGOG)

Invited Consultants

Janet Englund
Sam Katz
Michael Marcy
Debbie Saslow (ACS)
Aimee Kreimer (NCI)